Last reviewed · How we verify
Surgicel® Original
Surgicel® Original is a Hemostatic agent Small molecule drug developed by Takeda. It is currently in Phase 3 development for Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control).
Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites.
Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites. Used for Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control).
At a glance
| Generic name | Surgicel® Original |
|---|---|
| Sponsor | Takeda |
| Drug class | Hemostatic agent |
| Modality | Small molecule |
| Therapeutic area | Surgery/Hemostasis |
| Phase | Phase 3 |
Mechanism of action
The product works by converting to a gelatinous mass when it contacts blood, which physically promotes hemostasis and provides a scaffold for clot formation. It is absorbed by the body over 2-4 weeks and is commonly used during surgical procedures to control capillary, venous, and small arterial bleeding when conventional methods are ineffective.
Approved indications
- Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control)
Common side effects
- Encapsulation of fluid
- Foreign body reaction
- Infection at surgical site
Key clinical trials
- A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery (NA)
- GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery (NA)
- A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery (PHASE3)
- The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study) (NA)
- Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma (NA)
- Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery (PHASE3)
- TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery (PHASE3)
- Oxidized Cellulose hEmostAsis evaluatioN (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surgicel® Original CI brief — competitive landscape report
- Surgicel® Original updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Surgicel® Original
What is Surgicel® Original?
How does Surgicel® Original work?
What is Surgicel® Original used for?
Who makes Surgicel® Original?
What drug class is Surgicel® Original in?
What development phase is Surgicel® Original in?
What are the side effects of Surgicel® Original?
Related
- Drug class: All Hemostatic agent drugs
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Surgery/Hemostasis
- Indication: Drugs for Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control)
- Compare: Surgicel® Original vs similar drugs
- Pricing: Surgicel® Original cost, discount & access